Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study comparing S 18886 30 mg o.d. versus aspirin 100 mg o.d. administered orally.

Trial Profile

Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study comparing S 18886 30 mg o.d. versus aspirin 100 mg o.d. administered orally.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Aspirin; Terutroban sodium
  • Indications Cardiovascular disorders; Embolism and thrombosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 05 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top